Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy - The P-SELECT trial (WJOG10617G) - A randomised phase II trial by the West Japan Oncology Group

Kenro Hirata, Yasuo Hamamoto, Masahiko Ando, Chiyo K. Imamura, Kenichi Yoshimura, Kentaro Yamazaki, Shuichi Hironaka, Kei Muro

研究成果: Article査読

5 被引用数 (Scopus)

フィンガープリント

「Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy - The P-SELECT trial (WJOG10617G) - A randomised phase II trial by the West Japan Oncology Group」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

Medicine & Life Sciences